NASDAQ : MNPR
Monopar Therapeutics Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 71.91 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 482.67M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 444.88M |
| Enterprise Value | 310.79M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 6.71M |
| Shares Outstanding | 6.71M |
| Shares Change (YoY) | +45.84% |
| Shares Change (QoQ) | +0.08% |
| Owned by Insiders (%) | 7.25% |
| Owned by Institutions (%) | 82.74% |
| Float | 4.47M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 325.89 |
| PB Ratio | 3.61 |
| P/TBV Ratio | 3.42 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 33.56 |
| Quick Ratio | 33.44 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -19.50% |
| Return on Assets (ROA) | -14.64% |
| Return on Invested Capital (ROIC) | -15.08% |
| Return on Capital Employed (ROCE) | -16.89% |
| Weighted Average Cost of Capital (WACC) | 12.56% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$811,125 |
| Employee Count | 22 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.51 |
| 52-Week Price Change | -22.71% |
| 50-Day Moving Average | 90.26 |
| 200-Day Moving Average | 77.22 |
| Relative Strength Index (RSI) | 29.00 |
| Average Volume (20 Days) | 148,021 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.13M |
| Short Previous Month | 1.09M |
| Short % of Shares Out | 16.81% |
| Short % of Float | 25.26% |
| Short Ratio (days to cover) | 6.72 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -22.12M |
| Pretax Income | -17.84M |
| Net Income | -17.84M |
| EBITDA | n/a |
| EBIT | -22.12M |
| Earnings Per Share (EPS) | -$2.18 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 134.30M |
| Total Debt | 205,663 |
| Net Cash | 134.09M |
| Net Cash Per Share | $19.98 |
| Equity (Book Value) | 130.85M |
| Book Value Per Share | 19.50 |
| Working Capital | 130.75M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -12.18M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -12.18M |
| FCF Per Share | -$1.81 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -45.84% |
| Shareholder Yield | -45.84% |
| Earnings Yield | -3.29% |
| FCF Yield | -2.72% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $129.92 |
| Price Target Difference | 96.02% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Aug 13, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:5 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |